89 related articles for article (PubMed ID: 23535553)
21. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
22. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
24. [Molecular genetic tests in advanced non-small cell lung cancer: practical relevance].
Sebastian M; Niederle N; Thomas M; Reck M; Schmittel A; Fischer B; Overbeck T; Gröschel A; Deppermann M; Pirker R; Huber RM; Eberhardt W; Griesinger F
Dtsch Med Wochenschr; 2014 Oct; 139(41):2096-100. PubMed ID: 25268213
[No Abstract] [Full Text] [Related]
25. Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.
Balleine RL; Provan PJ; Pupo GM; Pathmanathan N; Cummings M; Farshid G; Salisbury EL; Bilous AM; Byth K; ; Mann GJ
Genes Chromosomes Cancer; 2010 Dec; 49(12):1082-94. PubMed ID: 20815029
[TBL] [Abstract][Full Text] [Related]
26. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
27. [Generic screening for breast cancer].
Ponti A; Giordano L
Epidemiol Prev; 1999; 23(4):369-71. PubMed ID: 10730478
[TBL] [Abstract][Full Text] [Related]
28. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
29. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
31. Screening for genetic risk of breast cancer.
Rosenthal TC; Puck SM
Am Fam Physician; 1999 Jan; 59(1):99-104, 106. PubMed ID: 9917577
[TBL] [Abstract][Full Text] [Related]
32. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
33. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
35. Treating the genetic make-up of breast cancer: a new fashion?
Linn SC; Jonkers J
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1065-7. PubMed ID: 17725409
[No Abstract] [Full Text] [Related]
36. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
37. Molecular testing in breast cancer.
Paoletti C; Hayes DF
Annu Rev Med; 2014; 65():95-110. PubMed ID: 24422569
[TBL] [Abstract][Full Text] [Related]
38. Polygenic model for predicting breast cancer risk via genome-wide polymorphisms.
Piccolo SR; Camp N; Frey LJ
AMIA Annu Symp Proc; 2008 Nov; ():1094. PubMed ID: 18999159
[TBL] [Abstract][Full Text] [Related]
39. Interleukin 1 genetic tests provide no support for reduction of preventive dental care.
Diehl SR; Kuo F; Hart TC
J Am Dent Assoc; 2015 Mar; 146(3):164-173.e4. PubMed ID: 25726343
[TBL] [Abstract][Full Text] [Related]
40. [Early genetic testing in nephrology - a diagnostic aid in ambiguous clinical situations].
Pasch A
Ther Umsch; 2010 Jul; 67(7):375-80. PubMed ID: 20577966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
